Oxford’s Nipah Virus Vaccine Granted PRIME Status by European Medicines Agency
The University of Oxford’s vaccine candidate against the deadly Nipah virus has received PRIME (PRIority MEdicines) designation from the European Medicines Agency (EMA)—a significant regulatory milestone that makes Oxford the first UK academic institution to secure this status. Launched in 2016, the EMA’s PRIME scheme supports the development of medicines that target conditions with high […]
Continue Reading